(:CLSN)

Sep 19, 2022 04:30 pm ET
Celsion Corporation Announces Company Name Change to Imunon, Inc.
Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, today announced a company name change to Imunon, Inc., reflecting the evolution of the Company’s business focus and its commitment to developing cutting-edge...
Sep 15, 2022 08:30 am ET
Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that its Phase I/II OVATION 2 Study with GEN-1 in advanced ovarian cancer has completed enrollment with...
Sep 12, 2022 06:30 pm ET
Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13
Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 24th Annual Global Investment...
Sep 07, 2022 09:15 am ET
Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company today announced that Dr. Corinne Le Goff, President and Chief Executive Officer will present a company overview and be available for 1x1 meetings at the upcoming H.C....
Sep 01, 2022 08:30 am ET
Celsion Corporation Highlights Progress in its DNA-based Vaccine Program
Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today provided an update on the progress made in the development of a DNA-based vaccine using its PLACCINE platform...
Aug 15, 2022 08:00 am ET
Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update
Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug-development company focused on DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the three and six months ended June 30, 2022, and provided an...
Aug 08, 2022 08:30 am ET
Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, August 15, 2022 to...
Jul 19, 2022 08:35 am ET
Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of (i) inducement...
Jul 19, 2022 08:30 am ET
Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer
Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Company’s Board of Directors has appointed biopharmaceutical leader Corinne Le Goff, Pharm D,...
Jun 24, 2022 08:35 am ET
Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing
Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the June 23rd Life Sciences Investor Forum are now available for on-demand viewing. REGISTER NOW OR LOGIN AT:...
Jun 21, 2022 04:21 pm ET
UPDATE - Life Sciences Investor Forum: Company Executives Present Live June 23rd 
Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with Zacks Small-Cap Research, today announced the agenda for the upcoming Life Sciences Investor Forum to be held on June 23rd. Individual investors,...
Jun 21, 2022 08:35 am ET
Life Sciences Investor Forum: Company Executives Present Live June 23rd 
Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with Zacks Small-Cap Research, today announced the agenda for the upcoming Life Sciences Investor Forum to be held on June 23rd. Individual investors,...
Jun 21, 2022 08:30 am ET
Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that following a pre-planned interim safety review of 87 as treated patients (46 patients in the...
May 16, 2022 08:00 am ET
Celsion Corporation Reports First Quarter 2022 Financial Results and Provides Business Update
Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug-development company focused on DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the quarter ended March 31, 2022, and provided an update on its...
May 10, 2022 08:30 am ET
Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates
Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today provided an update on the progress made in the Company’s two lead development programs. “We continue to make...
May 09, 2022 08:30 am ET
Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, May 16, 2022 to...
Apr 21, 2022 11:30 am ET
Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress
Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today presented its PLACCINE platform technology at the World Vaccine Congress taking place in Washington D.C. In an oral...
Apr 14, 2022 08:30 am ET
Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial at 2022 AACR Annual Meeting
Celsion Corporation (NASDAQ: CLSN) a clinical-stage company focused on DNA-based immunotherapy and next generation vaccines and Medidata, a Dassault Systèmes company, today announced that they presented their findings on the use of a Synthetic...
Apr 13, 2022 08:35 am ET
Thinking about buying stock in Antares Pharma, Celsion Corp, American Airlines, Kaleido Biosciences, or CTI BioPharma?
NEW YORK, April 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATRS, CLSN, AAL, KLDO, and CTIC.
Apr 12, 2022 08:30 am ET
Celsion Corporation to Highlight its PLACCINE Platform Technology During Oral Presentation at the World Vaccine Congress
Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced it would highlight its PLACCINE platform technology in an oral presentation at the World Vaccine Congress...
Apr 08, 2022 04:30 pm ET
Celsion Corporation Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules, of 1,328,274 shares of common stock at a purchase price...
Apr 06, 2022 08:30 am ET
Celsion and Medidata to Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial
Celsion Corporation (NASDAQ: CLSN) a clinical-stage company focused on DNA-based immunotherapy and next generation vaccines and Medidata, a Dassault Systèmes company, today announced that they will be presenting their findings on the use of a...
Apr 06, 2022 08:30 am ET
CELSION CORPORATION ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 1,328,274 shares of its common stock at a purchase price...
Apr 01, 2022 08:00 am ET
Celsion Corporation Reported Cash Position of $56.9 million at December 31, 2021
Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced the company reported a cash position of $56.9 million as of December 31, 2021 during its earnings...
Mar 31, 2022 08:30 am ET
Celsion Corporation Reports 2021 Financial Results and Provides Business Update
Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug-development company focused on DNA-based immunotherapy and next-generation vaccines, today announced financial results for the year ended December 31, 2021, and provided an update on...
Mar 24, 2022 09:00 am ET
Celsion Corporation to Hold Year-End 2021 Financial Results and Business Update Conference Call on Thursday, March 31, 2022
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Thursday, March 31, 2022 to...
Feb 28, 2022 09:00 am ET
Celsion Receives $1.4 Million from Sale of its New Jersey State Net Operating Losses
Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced it has received $1.4 million in net cash proceeds from the sale of approximately $1.5 million of its...
Feb 28, 2022 08:30 am ET
Celsion Corporation Announces Stock Consolidation
Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that, as previously authorized by its shareholders, the Company is implementing a consolidation (reverse...
Feb 17, 2022 08:30 am ET
Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that following a pre-planned interim safety review of 81 as treated patients randomized in the Phase I/II...
Jan 31, 2022 08:00 am ET
Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation DNA-based vaccines, announces it has engaged BIOQUAL, Inc., a preclinical testing contract research organization, to...
Jan 13, 2022 05:30 pm ET
Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced the closing of its previously announced registered direct offering with certain institutional...
Jan 10, 2022 08:45 pm ET
Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that it has entered into a securities purchase agreement with certain institutional investors...
Nov 29, 2021 08:30 am ET
Celsion Corporation Invited to Present Poster at Cytokine-Based Cancer Immunotherapies Summit
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announces that Khursheed Anwer, Ph.D., executive vice president and chief science officer, will be making a...
Nov 15, 2021 08:30 am ET
Celsion Corporation Reports Third Quarter 2021 Financial Results and Provides Business Update
Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug-development company focused on DNA-based immunotherapy and next-generation vaccines, today announced financial results for the three and nine months ended September 30, 2021, and provided an...
Nov 09, 2021 09:00 am ET
Celsion Corporation to Hold Third Quarter 2021 Financial Results and Business Update Conference Call on Monday, November 15, 2021
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, November 15, 2021 to...
Nov 08, 2021 09:00 am ET
Celsion Provides Update on its Application to Sell $1.5 Million of New Jersey Net Operating Losses
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced it was notified by the New Jersey Economic Development Authority (NJEDA) that the Company’s...
Nov 08, 2021 08:30 am ET
Celsion Corporation’s GEN-1 IL-12 Program to be Featured at Cytokine-Based Cancer Immunotherapies Summit
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announces that Khursheed Anwer, Ph.D., executive vice president and chief science officer, will be making a...
Oct 15, 2021 09:00 am ET
Celsion Corporation Announces Time of Oral Presentation at International Vaccines Congress
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA mediated immunotherapy and next-generation nucleic vaccines, announces that a time of Monday, October 18, 2021 at 7:30 a.m. Eastern time has been set for...
Oct 12, 2021 09:00 am ET
Celsion Corporation Announces Oral Presentation at International Vaccines Congress
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA mediated immunotherapy and next-generation nucleic vaccines, announces that Khursheed Anwer, Ph.D., executive vice president and chief science officer, will be...
Oct 11, 2021 09:00 am ET
Celsion GmbH Announces the Publication of an Article Reviewing the History of ThermoDox® Drug Development in Advanced Drug Delivery Reviews
Celsion GmbH, a wholly owned subsidiary of Celsion Corporation (NASDAQ: CLSN), a clinical-stage biotechnology company focused on DNA-based immunotherapy and next-generation vaccines, announces the journal Advanced Drug Delivery Reviews has...
Oct 05, 2021 09:00 am ET
Celsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial Capabilities
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announces the strengthening of its management team with a new hire and a promotion in its vaccine development...
Sep 30, 2021 09:00 am ET
Celsion to Present at Three Investment Conferences in October
Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that management will present at the following investment conferences in October: Chardan’s 5th Annual...
Sep 17, 2021 09:00 am ET
Celsion and Hainan Poly Pharm Sign Agreement to Manufacture Celsion’s DNA-based Vaccine
Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, and Hainan Poly Pharm Co. Ltd. (Shenzhen Stock Exchange 300630.SZ), a generics manufacturer dedicated to providing...
Sep 02, 2021 09:31 am ET
Thinking about buying stock in Innate Pharma, Biotricity, Nutanix, Celsion Corp, or Globalstar?
NEW YORK, Sept. 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IPHA, BTCY, NTNX, CLSN, and GSAT.
Sep 02, 2021 08:00 am ET
Celsion Reports T-cell and B-cell Response from In Vivo Studies with its PLACCINE DNA Vaccine Platform
Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced results from preclinical in vivo studies showing production of antibodies and cytotoxic T-cell response...
Aug 12, 2021 08:00 am ET
Celsion Corporation Reports Second Quarter 2021 Financial Results and Provides Business Update
Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug-development company focused on DNA-based immunotherapy and next-generation vaccines, today announced financial results for the three and six months ended June 30, 2021, and provided an...
Aug 05, 2021 08:00 am ET
Celsion Corporation to Hold Second Quarter 2021 Financial Results and Business Update Conference Call on Thursday, August 12, 2021
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. EDT on Thursday, August 12, 2021 to...
Jul 29, 2021 10:00 am ET
Results of Celsion’s OVATION 1 Study with GEN-1 in Patients with Advanced Ovarian Cancer Published in the Journal of Clinical Cancer Research
Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced the publication of data from its Phase 1b OVATION 1 Study with GEN-1 in combination with neoadjuvant...
Jul 19, 2021 08:00 am ET
Celsion Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that following a pre-planned interim safety review of 55 as treated patients randomized in the Phase I/II...
Jul 15, 2021 08:00 am ET
Celsion Corporation Expands Vaccine Advisory Board with the Addition of Dr. Dan H. Barouch and Dr. Luke D. Handke
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced the addition of Dan H. Barouch, M.D., Ph.D and Luke D. Handke, Ph.D. to its Vaccine Advisory...
Jul 01, 2021 08:00 am ET
Celsion GmbH Announces Commencement of Enrollment in Oxford University’s Phase 1 Study with ThermoDox® and Focused Ultrasound in Pancreatic Cancer
Celsion Corporation (NASDAQ: CLSN), Celsion GmbH, a wholly owned subsidiary of Celsion Corporation, a clinical-stage biotechnology company, announces commencement of enrollment in Oxford University’s Phase I PanDox study with ThermoDox® in...
Jun 23, 2021 08:00 am ET
Celsion Corporation Establishes Wholly Owned Subsidiary to Manage Investigator-Sponsored Development of ThermoDox®
Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, announces that its new wholly owned subsidiary, Celsion GmbH, will manage all current and future investigator-sponsored...
Jun 21, 2021 08:00 am ET
Celsion Corporation Enters into $10 Million Strategic Loan Facility with Silicon Valley Bank
Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, announces it has entered into a $10 million loan facility with Silicon Valley Bank (SVB). Celsion immediately used $6...
Jun 09, 2021 08:00 am ET
Celsion Appoints Christine A. Pellizzari to its Board of Directors
Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced the appointment of Christine A. Pellizzari to the Celsion Board of Directors, effective June 8, 2021. Ms....
Jun 08, 2021 08:00 am ET
Celsion Corporation Appoints Dr. Stacy R. Lindborg to its Board of Directors
Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced the appointment of Stacy R. Lindborg, Ph.D. to its Board of Directors, effective June 4, 2021. Dr....
Jun 07, 2021 05:00 pm ET
CELSION CORPORATION ANNOUNCES ADJOURNMENT OF ANNUAL MEETING
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced that its 2021 Annual Meeting of Stockholders, originally scheduled for Friday, June 4, 2021 at 10:00...
Jun 04, 2021 10:11 am ET
CELSION CORPORATION ANNOUNCES ADJOURNMENT OF ANNUAL MEETING
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced that its 2021 Annual Meeting of Stockholders, originally scheduled for today, Friday, June 4,...
Jun 02, 2021 08:00 am ET
Celsion Corporation Urges All Shareholders to Vote at the 2021 Annual Meeting to be Held on Friday June 4, 2021
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today reminded stockholders that the virtual Annual Meeting of Stockholders is scheduled for Friday, June 4,...
May 27, 2021 08:30 am ET
Celsion Corporation Urges All Shareholders to Vote at the 2021 Annual Meeting to be Held on Friday June 4, 2021
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today reminded stockholders that the virtual Annual Meeting of Stockholders is scheduled for Friday, June 4,...
May 14, 2021 08:00 am ET
Celsion Corporation Reports First Quarter 2021 Financial Results and Provides Business Update
Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today announced financial results for the three months ended March 31, 2021, and provided an update on...
May 11, 2021 08:00 am ET
Celsion Receives $1.85 Million from the Sale of its New Jersey State Net Operating Losses
Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced it has received $1.85 million in net cash proceeds from the sale of approximately $2.0 million of its...
May 07, 2021 08:30 am ET
Celsion Corporation to Hold First Quarter 2021 Financial Results and Business Update Conference Call on Friday, May 14, 2021
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 10:00 a.m. EDT on Friday, May 14, 2021 to...
Apr 22, 2021 08:30 am ET
Celsion Management Participates in Alliance Global Partners Virtual Series
Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that management participated in Alliance Global Partners’ (AGP) Virtual Series on April 21, 2021. Michael...
Apr 05, 2021 05:00 pm ET
CELSION CORPORATION ANNOUNCES CLOSING OF $15 MILLION REGISTERED DIRECT OFFERING
Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its previously announced registered direct offering of 11,538,462 shares of common stock at a purchase price of $1.30 per share, resulting in net...
Apr 01, 2021 08:30 am ET
Poster on Celsion Corporation’s Phase I/II OVATION 2 Study Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer
Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that a poster highlighting the Company’s ongoing Phase I/II OVATION 2 Study with GEN-1 in advanced ovarian...
Mar 31, 2021 08:00 am ET
CELSION CORPORATION ANNOUNCES $15 MILLION REGISTERED DIRECT OFFERING
Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 11,538,462 shares of its common stock at a purchase price of $1.30...
Mar 19, 2021 08:45 am ET
Celsion Corporation Reports 2020 Financial Results and Provides Business Update
Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today announced financial results for the year ended December 31, 2020 and provided an update on clinical...
Mar 12, 2021 08:45 am ET
Celsion Corporation to Hold Year-End 2020 Financial Results and Business Update Conference Call on Friday, March 19, 2021
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. EDT on Friday, March 19, 2021 to...
Mar 02, 2021 08:45 am ET
Poster on Celsion Corporation’s Phase I/II OVATION 2 Study to be Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that a poster on the Company’s Phase I/II OVATION 2 Study with GEN-1 in advanced ovarian...
Feb 26, 2021 08:45 am ET
Celsion Corporation to Participate in the Virtual 33ʳᵈ Annual Roth Conference
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that management will be holding one-on-one meetings with investors during the Virtual 33rd...
Feb 25, 2021 08:45 am ET
Celsion Corporation Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Including Encouraging Interim Resection Scores
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today provided an update on its Phase I/II OVATION 2 Study with GEN-1 in patients with advanced ovarian...
Feb 23, 2021 08:00 am ET
Celsion Receives $2 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program
Celsion Corporation (NASDAQ: CLSN), a clinical stage development company focused on DNA based immunotherapy and next generation vaccines, today announced it has received approval from the New Jersey Economic Development Authority’s (NJEDA)...
Feb 22, 2021 07:30 am ET
Celsion Corporation Receives FDA Fast Track Designation for GEN-1 in Advanced Ovarian Cancer
Celsion Corporation (NASDAQ: CLSN), a clinical stage development company focused on DNA based immunotherapy and next generation vaccines, today announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA)...
Feb 22, 2021 07:30 am ET
Thinking about buying stock in Celsion Corp, Can Fite Biopharma, ConforMIS Inc, Citius Pharmaceuticals, or Vuzix Corp?
NEW YORK, Feb. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLSN, CANF, CFMS, CTXR, and VUZI.
Feb 12, 2021 08:31 am ET
Thinking about buying stock in Can Fite Biopharma, Celsion Corp, Remark Holdings, Plus Therapeutics, or SenesTech?
NEW YORK, Feb. 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CANF, CLSN, MARK, PSTV, and SNES.
Feb 12, 2021 08:30 am ET
Celsion Corporation Announces Formation of Vaccine Advisory Board
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the formation of a Vaccine Advisory Board and the appointment of its first two members: Britt A. Glaunsinger, Ph.D., Professor, Virology & Molecular...
Feb 11, 2021 08:31 am ET
Thinking about buying stock in Seelos Therapeutics, Celsion Corp, Zosano Pharma, Outlook Therapeutics, or Infinity Pharmaceuticals?
NEW YORK, Feb. 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SEEL, CLSN, ZSAN, OTLK, and INFI.
Feb 11, 2021 08:30 am ET
Celsion Corporation Issues Letter to Stockholders
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Michael H. Tardugno, the company’s chairman, president and chief executive officer, issued a letter to stockholders providing: Further details on...
Jan 28, 2021 08:00 am ET
Celsion Corporation Files Provisional U.S. Patent Application for a Broad Range of Next Generation DNA Vaccines
Celsion Corporation (NASDAQ: CLSN), a clinical stage biotechnology company, in response to the long-term threat of coronaviruses and other potential pandemic causing infectious agents, today announced the filing of a provisional U.S. patent...
Jan 26, 2021 05:00 pm ET
CELSION CORPORATION ANNOUNCES CLOSING OF $35 MILLION REGISTERED DIRECT OFFERING OF COMMON STOCK PRICED AT-THE-MARKET UNDER NASDAQ RULES
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the closing of its previously announced registered direct offering of 25,925,925 shares of common stock at a purchase price of $1.35 per share, priced...
Jan 22, 2021 09:50 am ET
Thinking about buying stock in AMC Entertainment, AzurRx BioPharma, Celsion Corp, Transocean, or Biolase?
NEW YORK, Jan. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, AZRX, CLSN, RIG, and BIOL.
Jan 22, 2021 08:40 am ET
CELSION CORPORATION ANNOUNCES $35 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 25,925,925 shares of its common stock at a purchase price of $1.35...
Jan 21, 2021 07:30 am ET
Thinking about buying stock in Celsion Corp, Jaguar Health, Precision BioSciences, electroCore, or Lipocine?
NEW YORK, Jan. 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLSN, JAGX, DTIL, ECOR, and LPCN.
Dec 29, 2020 09:37 am ET
DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Celsion Corporation and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Celsion Corporation (“Celsion” or “the Company”) (NASDAQ:
Dec 29, 2020 09:10 am ET
FINAL CLSN DEADLINE TODAY: ROSEN, RESPECTED INVESTOR COUNSEL, Reminds Celsion Corporation Investors of Important Tuesday Deadline in Securities Class Action – CLSN
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the “Class Period”), of the important December 29, 2020 lead...
Dec 28, 2020 11:55 am ET
DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Celsion Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, Dec. 28, 2020 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Celsion Corporation ("Celsion" or "the Company") (NASDAQ: CLSN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Dec 26, 2020 09:00 am ET
DEC. 29 DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Celsion Corporation – CLSN
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the “Class Period”). To join the class action, go...
Dec 24, 2020 11:00 am ET
CELSION DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Celsion Corporation - CLSN
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Celsion Corporation (NASDAQ: CLSN) from November 2, 2015 through July 10, 2020, inclusive (the “Class Period”). The lawsuit seeks...
Dec 22, 2020 04:02 pm ET
ROSEN, RECOGNIZED INVESTOR COUNSEL, Reminds Celsion Corporation Investors of Important December 29 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact t
NEW YORK, Dec. 22, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the "Class Period"), of the important December 29, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Celsion investors under the federal securities laws.
Dec 18, 2020 11:49 am ET
LOOMING DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Celsion Corporation – CLSN
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the “Class Period”). To join the class action, go...
Dec 16, 2020 05:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BMW, Zosano Pharma, Celsion, and Citigroup and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Bayerische Motoren Werke AG (“BMW”) (Other OTC: BMWYY, BAMXF), Zosano Pharma...
Dec 15, 2020 12:27 pm ET
Pawar Law Group Announces a Securities Class Action Lawsuit Against Celsion Corporation; IMPORTANT DEC. 29 DEADLINE- CLSN
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Celsion Corporation (NASDAQ: CLSN) from November 2, 2015 through July 10, 2020, inclusive (the “Class Period”). The lawsuit seeks...
Dec 13, 2020 12:40 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Celsion Corporation of Class Action Lawsuit and Upcoming Deadline – CLSN
Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Celsion Corporation (“Celsion” or the “Company”) (NASDAQ: CLSN).   The class action, filed in United States District Court for the District of New...
Dec 12, 2020 10:00 am ET
LOOMING DEADLINE Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Celsion Corporation – CLSN
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the “Class Period”). To join the class action, go...
Dec 10, 2020 04:19 pm ET
ROSEN, TOP RANKED INVESTOR COUNSEL, Reminds Celsion Corporation Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – CL
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the “Class Period”), of the important December 29, 2020 lead...
Dec 09, 2020 05:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BMW, Zosano Pharma, Celsion, and Citigroup and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Bayerische Motoren Werke AG (“BMW”) (Other OTC: BMWYY, BAMXF), Zosano Pharma...
Dec 08, 2020 12:16 pm ET
CLSN DEC. 29 DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Celsion Corporation - CLSN
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Celsion Corporation (NASDAQ: CLSN) from November 2, 2015 through July 10, 2020, inclusive (the “Class Period”). The lawsuit seeks...
Dec 07, 2020 10:54 pm ET
ROSEN, A LEADING LAW FIRM, Reminds Celsion Corporation Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - CLSN
NEW YORK, Dec. 7, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the "Class Period"), of the important December 29, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Celsion investors under the federal securities laws.
Dec 07, 2020 09:14 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Celsion Corporation of Class Action Lawsuit and Upcoming Deadline – CLSN
Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Celsion Corporation (“Celsion” or the “Company”) (NASDAQ: CLSN).   The class action, filed in United States District Court for the District of New...
Dec 03, 2020 05:16 pm ET
ROSEN, RESPECTED INVESTOR COUNSEL, Reminds Celsion Corporation Investors of Important December 29 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact th
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the “Class Period”), of the important December 29, 2020 lead...
Dec 03, 2020 11:30 am ET
Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Celsion Corporation – CLSN
Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the “Class Period”). To join the class action, go...
Dec 03, 2020 03:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Celsion Corporation of Class Action Lawsuit and Upcoming Deadline - CLSN
NEW YORK, Dec. 3, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Celsion Corporation ("Celsion" or the "Company") (NASDAQ: CLSN).  The class action, filed in United States District Court for the District of New Jersey, and docketed under 20-cv-015228, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired Celsion securities between November 2, 2015 and July 10, 2020, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of
Dec 02, 2020 07:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BMW, Zosano Pharma, Celsion, and Citigroup and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Bayerische Motoren Werke AG (“BMW”) (Other OTC: BMWYY, BAMXF), Zosano Pharma...
Nov 30, 2020 10:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Celsion Corporation of Class Action Lawsuit and Upcoming Deadline – CLSN
Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Celsion Corporation (“Celsion” or the “Company”) (NASDAQ: CLSN).   The class action, filed in United States District Court for the District of New...
Nov 26, 2020 10:00 am ET
CLSN CUTOFF: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Celsion Corporation – CLSN
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the “Class Period”). To join the class action, go...
Nov 26, 2020 12:01 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Celsion Corporation of Class Action Lawsuit and Upcoming Deadline – CLSN
Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Celsion Corporation (“Celsion” or the “Company”) (NASDAQ: CLSN). The class action, filed in United States District Court for the District of New Jersey,...
Nov 25, 2020 06:30 pm ET
ROSEN, A TRUSTED AND TOP RANKED LAW FIRM, Reminds Celsion Corporation Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Fir
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the “Class Period”), of the important December 29, 2020 lead...
Nov 24, 2020 07:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Celsion, Citigroup, Raytheon, Intercept Pharmaceuticals and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Celsion Corporation (NASDAQ: CLSN), Citigroup, Inc. (NYSE: C), Raytheon...
Nov 24, 2020 07:00 pm ET
CLSN: Pawar Law Group Announces a Securities Class Action Lawsuit Against Celsion Corporation; IMPORTANT DEADLINE- CLSN
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Celsion Corporation (NASDAQ: CLSN) from November 2, 2015 through July 10, 2020, inclusive (the “Class Period”). The lawsuit seeks...
Nov 22, 2020 02:08 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Celsion Corporation of Class Action Lawsuit and Upcoming Deadline – CLSN
Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Celsion Corporation (“Celsion” or the “Company”) (NASDAQ: CLSN).   The class action, filed in United States District Court for the District of New...
Nov 20, 2020 06:00 pm ET
ROSEN, LEADING INVESTOR COUNSEL, Reminds Celsion Corporation Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – CLSN
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the “Class Period”), of the important December 29, 2020 lead...
Nov 19, 2020 11:00 am ET
CLSN DEADLINE ALERT: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Celsion Corporation – CLSN
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the “Class Period”). To join the class action, go...
Nov 18, 2020 08:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Zosano Pharma, Celsion, Citigroup, and Raytheon and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Zosano Pharma Corporation (NASDAQ: ZSAN), Celsion Corporation (NASDAQ: CLSN),...
Nov 16, 2020 10:01 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Celsion Corporation of Class Action Lawsuit and Upcoming Deadline – CLSN
Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Celsion Corporation (“Celsion” or the “Company”) (NASDAQ: CLSN).   The class action, filed in United States District Court for the District of New...
Nov 16, 2020 08:30 am ET
Celsion Corporation Reports Third Quarter 2020 Financial Results and Provides Business Update
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the three and nine months ended September 30, 2020, and provided an update on clinical development programs with GEN-1, its DNA-mediated...
Nov 13, 2020 02:46 pm ET
ROSEN, LEADING INVESTOR COUNSEL, Reminds Celsion Corporation Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – CLSN
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the “Class Period”), of the important December 29, 2020 lead...
Nov 13, 2020 11:00 am ET
CLSN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Celsion Corporation Shareholders With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: December 28, 2020
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
Nov 12, 2020 03:38 pm ET
SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Celsion Corporation – CLSN; IMPORTANT DEADLINE - CLSN
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Celsion Corporation (NASDAQ: CLSN) from November 2, 2015 through July 10, 2020, inclusive (the “Class Period”). The lawsuit seeks...
Nov 11, 2020 08:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BMW, Zosano Pharma, Celsion, and Citigroup and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Bayerische Motoren Werke AG (“BMW”) (Other OTC: BMWYY, BAMXF), Zosano Pharma...
Nov 11, 2020 04:41 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Celsion Corporation of Class Action Lawsuit and Upcoming Deadline – CLSN
Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Celsion Corporation (“Celsion” or the “Company”) (NASDAQ: CLSN). The class action, filed in United States District Court for the District of New Jersey,...
Nov 11, 2020 02:36 pm ET
CLSN STOCK ALERT: Zhang Investor Law Announces Securities Class Action Lawsuit Against Celsion Corporation – CLSN
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the “Class Period”). To join the class action, go...
Nov 11, 2020 11:00 am ET
CLSN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Celsion Corporation Shareholders of Class Action and Lead Plaintiff Deadline: December 28, 2020
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against of Celsion Corporation ("Celsion" or "the Company") (NASDAQ: CLSN) and certain of its officers, on behalf of...
Nov 09, 2020 06:30 pm ET
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Reminds Celsion Corporation Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - C
NEW YORK, Nov. 9, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the "Class Period"), of the important December 29, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Celsion investors under the federal securities laws.
Nov 09, 2020 08:30 am ET
Celsion Corporation to Hold Third Quarter 2020 Financial Results and Business Update Conference Call on Monday, November 16, 2020
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the third quarter ended September 30, 2020 and provide an update on its development programs for GEN-1, an IL-12 DNA...
Nov 07, 2020 05:22 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Celsion Corporation of Class Action Lawsuit and Upcoming Deadline – CLSN
Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Celsion Corporation (“Celsion” or the “Company”) (NASDAQ: CLSN).   The class action, filed in United States District Court for the District of New...
Nov 07, 2020 02:30 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Celsion Corporation Investors of Important December 29 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the F
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the “Class Period”), of the important December 29, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Celsion investors under the federal securities laws.
Nov 05, 2020 11:00 am ET
CLSN Investor Alert - Bronstein, Gewirtz & Grossman, LLC Notifies Celsion Corporation Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: December 28, 2020
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against of Celsion Corporation ("Celsion" or "the Company") (NASDAQ: CLSN) and certain of its officers, on behalf of shareholders...
Nov 04, 2020 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Zosano Pharma, Celsion, Citigroup, and Raytheon and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Zosano Pharma Corporation (NASDAQ: ZSAN), Celsion Corporation (NASDAQ: CLSN),...
Nov 03, 2020 06:49 pm ET
ROSEN, TRUSTED AND LEADING INVESTOR COUNSEL, Announces Filing of Securities Class Action Lawsuit Against Celsion Corporation; Encourages Investors with Losses in Excess of $100K to Contact the Firm -
NEW YORK, Nov. 3, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Celsion investors under the federal securities laws.
Nov 03, 2020 03:46 pm ET
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Celsion Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Fi
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Celsion Corporation (“Celsion” or “the Company”) (NASDAQ:
Nov 03, 2020 12:57 pm ET
Moore Kuehn, PLLC Encourages Investors of CLSN, PGEN or TCMD to Contact Law Firm
Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding possible breaches of fiduciary duties related to whether insiders caused their companies to make false...
Nov 03, 2020 10:00 am ET
CLSN Investor Alert - Bronstein, Gewirtz & Grossman, LLC Notifies Celsion Corporation Shareholders With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: December 28, 2020
NEW YORK, Nov. 3, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against of Celsion Corporation 
Nov 02, 2020 02:37 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Celsion Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Celsion Corporation (“Celsion” or “the Company”) (NASDAQ:
Nov 02, 2020 11:34 am ET
ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Celsion Corporation – CLSN
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Celsion investors under the federal securities laws.
Oct 30, 2020 10:14 pm ET
/C O R R E C T I O N -- Pomerantz LLP/
In the news release, Pomerantz Law Firm Announces the Filing of a Class Action against Celsion Corporation Certain Officers - CLSN, issued 30-Oct-2020 by Pomerantz LLP over PR Newswire, we are advised by the company that the second paragraph, first sentence, should read "you have until December 29, 2020" rather than "you have until December 28, 2020" as originally issued inadvertently. The complete, corrected release follows:
Oct 30, 2020 06:00 pm ET
CELSION ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Celsion Corporation and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of investors that purchased Celsion Corporation (NASDAQ: CLSN) securities between November 2, 2015 to July 10, 2020 (the “Class Period”). Investors have until December 28, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Oct 30, 2020 01:30 am ET
Pomerantz Law Firm Announces the Filing of a Class Action against Celsion Corporation Certain Officers - CLSN
NEW YORK, Oct. 30, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Celsion Corporation ("Celsion" or the "Company") (NASDAQ: CLSN). The class action, filed in United States District Court for the District of New Jersey, and docketed under 20-cv-015228, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired Celsion securities between November 2, 2015 and July 10, 2020, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of
Oct 12, 2020 08:00 am ET
Celsion Corporation Issues Letter to Stockholders
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Michael H. Tardugno, the company’s chairman, president and chief executive officer, issued the following letter to stockholders providing an update on...
Sep 08, 2020 08:35 am ET
Celsion Announces Common Stock Purchase Agreement with Lincoln Park Capital and Provides Updates on OVATION 2 Study
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today provided an update on the OVATION 2 Study with GEN-1 in advanced ovarian cancer patients. Celsion also announced it has entered into a common stock purchase agreement...
Sep 02, 2020 08:00 am ET
Celsion Corporation Restructures its Strategic Loan Facility
Celsion Corporation (NASDAQ: CLSN) (“Celsion” or “the Company”), an oncology drug development company, today announced that on August 28, 2020 it entered into an amendment to its existing $10 million loan agreement with Horizon Technology Finance...
Aug 14, 2020 08:00 am ET
Celsion Corporation Reports Second Quarter 2020 Financial Results and Provides Business Update
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the three and six months ended June 30, 2020, and provided an update on clinical development programs with GEN-1, its DNA-mediated IL-12...
Aug 07, 2020 08:30 am ET
Celsion Corporation to Hold Second Quarter 2020 Financial Results and Business Update Conference Call on Friday, August 14, 2020
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the second quarter ended June 30, 2020 and provide an update on its development programs for GEN-1, an IL-12 DNA...
Aug 04, 2020 08:30 am ET
Celsion Corporation to Continue Following Patients in Phase III OPTIMA Study for Overall Survival
Celsion Corporation (NASDAQ: CLSN), an oncology focused drug-development company, today provided an update on its ongoing review of unblinded data from the second pre-planned interim analysis of the global Phase III OPTIMA Study of ThermoDox® in...
Jul 27, 2020 08:30 am ET
Celsion Corporation Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer
Celsion Corporation (NASDAQ: CLSN), an oncology focused drug-development company, today announced the randomization of the first two patients in the Phase II portion of the Phase I/II OVATION 2 Study with GEN-1 in advanced ovarian cancer. The...
Jul 14, 2020 08:30 am ET
Celsion Corporation to Hold Conference Call to Discuss OPTIMA Study on Wednesday, July 15, 2020 at 11:00 a.m. Eastern Time
Celsion Corporation (NASDAQ: CLSN) will host a conference call and webcast on Wednesday, July 15 at 11:00 a.m. Eastern time to discuss its current observations about the results of the OPTIMA Study and the Company’s next steps. To access the...
Jul 13, 2020 08:30 am ET
Celsion Corporation Receives Recommendation from Independent Data Monitoring Committee to Consider Stopping the Phase III OPTIMA Study
Celsion Corporation (NASDAQ: CLSN), an oncology focused drug-development company, today announced that it has received a recommendation from the independent Data Monitoring Committee (DMC) to consider stopping the global Phase III OPTIMA Study of...
Jun 25, 2020 08:00 am ET
Celsion Affirms July Timing for Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, today affirmed that the independent Data Monitoring Committee (iDMC) is scheduled to meet during the first half of July to conduct the second pre-planned interim safety and...
Jun 24, 2020 04:15 pm ET
Celsion Corporation Announces Closing of Public Offering of Common Stock
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the closing of its previously announced public offering of 2,666,667 shares of common stock, resulting in net proceeds of $9.3 million, after deducting...
Jun 22, 2020 03:00 pm ET
Celsion Corporation Announces Pricing of $10 Million Underwritten Offering of Common Stock
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the entry into an underwriting agreement relating to the sale of 2,666,667 shares of its common stock at an offering price of $3.75 per share, less...
Jun 19, 2020 09:31 am ET
Thinking about buying stock in Salem Media Group, Dynavax Technologies, Celsion Corp, Hertz Global Holdings, or MGM Resorts?
NEW YORK, June 19, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SALM, DVAX, CLSN, HTZ, and MGM.
Jun 17, 2020 09:31 am ET
Thinking about buying stock in Celsion Corp, Alkaline Water Company, Salem Media Group, Ocular Therapeutix, or Delta Air Lines?
NEW YORK, June 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLSN, WTER, SALM, OCUL, and DAL.
Jun 01, 2020 09:31 am ET
Thinking about buying stock in Ovid Therapeutics, Celsion Corp, Aileron Therapeutics, Cronos Group, or Bank of America?
NEW YORK, June 1, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OVID, CLSN, ALRN, CRON, and BAC.
May 29, 2020 08:30 am ET
Celsion Reports Data Safety Monitoring Board Recommendation to Proceed to Phase II of the OVATION 2 Study in Advanced Ovarian Cancer
Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced the final recommendations of the Data Safety Monitoring Board (DSMB) following completion of the Phase I dose-finding and tolerance portion of the...
May 27, 2020 09:31 am ET
Thinking about buying stock in Biocept, Celsion Corp, Tilray, Altimmune, or Ford?
NEW YORK, May 27, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIOC, CLSN, TLRY, ALT, and F.
May 15, 2020 08:00 am ET
Celsion Corporation Reports First Quarter 2020 Financial Results and Provides Business Update
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the three months ended March 31, 2020, and provided an update on clinical development programs with ThermoDox®, its proprietary...
May 08, 2020 09:00 am ET
Celsion Corporation to Hold First Quarter 2020 Financial Results Conference Call on Friday, May 15, 2020
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the first quarter ended March 31, 2020 and provide an update on its development programs for ThermoDox®, its...
Apr 23, 2020 08:30 am ET
Celsion Receives $2.5 Million in Non-Dilutive Funding from the Sale of its New Jersey State Net Operating Losses and Grant Funding Under the Paycheck Protection Program
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced it has received $1.82 million of net cash proceeds from the sale of approximately $1.9 million of its unused New Jersey net operating losses (NOLs) and...
Apr 15, 2020 08:30 am ET
Celsion Reports that Sufficient Events Have Been Reached for the Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces that the prescribed minimum number of events of 158 patient deaths has been reached for the second pre-specified interim analysis of the OPTIMA Phase III Study with...
Mar 26, 2020 08:00 am ET
Celsion’s OVATION 1 Study with GEN-1 in Ovarian Cancer Shows Strong Progression-Free Survival Treatment Effect Utilizing Medidata Synthetic Control Arm
Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today jointly announced with Medidata, a Dassault Systèmes company, that examining matched patient data provided by Medidata in a synthetic control arm (SCA) with...
Mar 25, 2020 04:15 pm ET
Celsion Corporation Reports 2019 Financial Results and Provides Business Update
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the year ended December 31, 2019 and provided an update on clinical development programs with ThermoDox®, its proprietary heat-activated...
Mar 23, 2020 08:00 am ET
Celsion’s GEN-1 Immunotherapy Receives Orphan Drug Designation from the European Medicines Agency
Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has recommended that GEN-1 be designated as an orphan medicinal...
Mar 19, 2020 08:30 am ET
Celsion Corporation to Hold Year-End 2019 Financial Results Conference Call on Thursday, March 26, 2020
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the year ended December 31, 2019 and provide an update on its development programs for ThermoDox®, its proprietary...
Mar 19, 2020 08:00 am ET
Celsion Announces Highly Encouraging Initial Clinical Results from the Phase I Portion of the Phase I/II OVATION 2 Study with GEN-1 in Patients with Advanced Ovarian Cancer
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced highly encouraging initial clinical data from the first 15 patients enrolled in the ongoing Phase I/II OVATION 2 Study for patients newly diagnosed with Stage...
Mar 03, 2020 08:30 am ET
Celsion CEO Issues Letter to Stockholders
Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announces that Michael H. Tardugno, the company’s chairman, president and chief executive officer, issued the following letter to stockholders. To My Fellow...
Feb 28, 2020 08:45 am ET
Celsion Corporation Prices $4.8 Million Registered Direct Offering
Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 4,571,428 shares of the Company’s common stock, par value...
Feb 06, 2020 09:25 am ET
Celsion Corporation Announces DSMB has Confirmed Initial Safety of Weekly GEN-1 Dosing at 100 mg/m² in 15 Randomized Patients with Advanced Ovarian Cancer
Celsion Corporation (NASDAQ: CLSN) today announced that the independent Data Safety Monitoring Board (DSMB) has completed its initial safety review of data from the first fifteen patients treated with the first four neoadjuvant doses of GEN-1 at...
Feb 04, 2020 08:30 am ET
Principal Investigator Professor Riccardo Lencioni Presents Celsion ThermoDox® Trial Data at SPECTRUM 2020 Interventional Oncology Conference
Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces that Prof. Riccardo Lencioni, M.D., FSIR, EBIR delivered a presentation titled “Thermally-Sensitive Ablation Enhancers: Where Do We Stand?” at the SPECTRUM 2020...
Dec 18, 2019 08:00 am ET
Celsion’s New Subsidiary in China to Serve as Beachhead for Commercializing ThermoDox® in China and Southeast Asia
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, announces the signing of a memorandum of understanding (MOU) with officials from the Hangzhou Yuhang Economic Development Area to establish a subsidiary in the Yuhang...
Dec 17, 2019 08:00 am ET
Celsion Receives $2.0 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced it has received approval from the New Jersey Economic Development Authority’s (NJEDA) Technology Business Tax Certificate Transfer (NOL) program to sell $2.0...
Nov 14, 2019 04:05 pm ET
Celsion Corporation Reports Third Quarter 2019 Financial Results and Provides Business Update
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the three-month and nine-month periods ended September 30, 2019 and provided an update on its development programs for ThermoDox® and...
Nov 14, 2019 08:00 am ET
Celsion Announces Publication of Research on Fluorescence Imaging of ThermoDox® Uptake in International Journal of Hyperthermia
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that results from an independent study of a lyso-thermosensitive liposomal doxorubicin (LTLD) was published in the peer-reviewed publication, International...
Nov 08, 2019 08:30 am ET
Celsion Corporation to Hold Third Quarter 2019 Financial Results Conference Call on Friday, November 15, 2019
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended September 30, 2019 and provide an update on its development programs for ThermoDox®, its proprietary...
Nov 05, 2019 08:00 am ET
Celsion Announces DSMB Recommendation to Continue GEN-1 at 100mg/m² Dose to Complete the Phase I Portion of OVATION 2 Study in Ovarian Cancer
Celsion Corporation (NASDAQ: CLSN) today announced that the independent Data Safety Monitoring Board (DSMB) has completed its safety review of data from the first eight patients enrolled in the ongoing Phase I/II OVATION 2 Study. Based on the...
Nov 04, 2019 08:00 am ET
Celsion Reports Unanimous Independent Data Monitoring Committee Recommendation to Continue the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the independent Data Monitoring Committee (iDMC) has unanimously recommended the OPTIMA Study continue according to protocol. The recommendation was...
Oct 01, 2019 08:00 am ET
Celsion Strengthens Its 2019 Balance Sheet with the Approval of Its Application to Sell Net Operating Losses for $2.1 Million in Non-Dilutive Funding
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced it has received approval from the New Jersey Economic Development Authority’s (NJEDA) Technology Business Tax Certificate Transfer (NOL) program to sell the...
Sep 30, 2019 02:30 pm ET
Celsion to Present at the Chardan 3rd Annual Genetic Medicines Conference
Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces that Michael Tardugno, Chairman, President and Chief Executive Officer and Khursheed Anwer, Executive Vice President and Chief Scientific Officer will present at...
Sep 23, 2019 08:00 am ET
Celsion Co-sponsors Hepatocellular Carcinoma Symposium at the International Liver Cancer Association (ILCA) Annual Conference
Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces it co-sponsored a symposium focused on hepatocellular carcinoma (HCC) at the recent 13th Annual Conference of the International Liver Cancer Association (ILCA)....
Aug 27, 2019 08:00 am ET
Celsion Announces Publication of Findings from Single-Site Study in China of ThermoDox® Plus RFA in the Journal of Cancer Research and Therapeutics
Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces that a study from a single site in China titled “Thermosensitive liposomal doxorubicin plus radiofrequency ablation increased tumor destruction and improved...
Aug 14, 2019 04:30 pm ET
Celsion Corporation Reports Second Quarter 2019 Financial Results and Provides Business Update
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the three and six months ended June 30, 2019 and provided an update on its development programs for ThermoDox® and GEN-1. The Company's...
Aug 13, 2019 08:00 am ET
Celsion Announces Publication of Results of National Institutes of Health (NIH) Analysis of ThermoDox® in Journal of Vascular and Interventional Radiology
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that results from an independent analysis of the Company’s ThermoDox® HEAT Study conducted by the National Institutes of Health (NIH) were published in the...
Aug 09, 2019 08:30 am ET
Celsion's GEN-1 Immunotherapy Highlighted in Oppenheimer's Expert Call on Ovarian Cancer Treatment Landscape and Emerging Opportunities
Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces that Premal H. Thaker, M.D., MSc., Professor of Obstetrics and Gynecology-Division of Gynecologic Oncology at Washington University School of Medicine in St. Louis,...
Aug 08, 2019 08:30 am ET
Celsion Corporation to Hold Second Quarter 2019 Financial Results Conference Call on Thursday, August 15, 2019
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended June 30, 2019 and provide an update on its development programs for ThermoDox®, its proprietary...
Aug 05, 2019 09:00 am ET
Celsion Announces Data Lock for First Interim Analysis in OPTIMA Phase III Study of ThermoDox® in Primary Liver Cancer
Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces the prescribed number of events has been reached for the first prespecified interim analysis of the OPTIMA Phase III Study with ThermoDox® plus RFA (radiofrequency...
Jun 20, 2019 08:30 am ET
Celsion Announces IRB Approval to Begin a Clinical Study of ThermoDox® Plus High Intensity Focused Ultrasound in Breast Cancer Patients at University Medical Center Utrecht in the Netherlands
Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces that the University Medical Center Utrecht in the Netherlands has received Institutional Review Board (IRB) approval to begin a Phase I study to determine the...
May 15, 2019 08:00 am ET
Celsion Corporation Reports First Quarter 2019 Financial Results and Provides Business Update
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the quarter ended March 31, 2019 and provided an update on its development programs for ThermoDox®, its proprietary heat-activated...
May 08, 2019 05:00 pm ET
Celsion Corporation to Hold First Quarter 2019 Financial Results Conference Call on Wednesday, May 15, 2019
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March 31, 2019 and provide an update on its development programs for ThermoDox®, its proprietary...
Apr 17, 2019 08:00 am ET
Celsion Corporation Announces Issuance of New Patent for ThermoDox®
Celsion Corporation (NASDAQ: CLSN), a clinical stage oncology drug development company, today announced that the United States Patent and Trademark Office has granted U.S. Patent No. 10,251,901 B2 – Thermosensitive Nanoparticle Formulations and...
Apr 12, 2019 08:30 am ET
Celsion Corporation to Participate in Two Investor Conferences in May 2019
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Michael Tardugno, Chairman, President and Chief Executive Officer and Jeffrey Church, Executive Vice President and Chief Financial Officer, will attend...
Apr 12, 2019 08:00 am ET
Celsion Corporation to Hold First Quarter 2019 Financial Results Conference Call on Wednesday, May 15, 2019
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March 31, 2019 and provide an update on its development programs for ThermoDox®, its proprietary...
Apr 12, 2019 07:10 am ET
Detailed Research: Economic Perspectives on Lamb Weston, The Mosaic, WD-40, Ichor, Celsion, and Transatlantic Petroleum — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Lamb Weston Holdings Inc. (NYSE:LW), The Mosaic Company (NYSE:MOS), WD-40...
Apr 11, 2019 12:34 pm ET
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Celsion Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK, April 11, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Celsion Corporation (NASDAQ: CLSN).
Mar 29, 2019 08:00 am ET
Celsion Corporation Reports 2018 Financial Results
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the year ended December 31, 2018 and provided an update on its development programs for ThermoDox®, its proprietary heat-activated...
Mar 22, 2019 08:30 am ET
Celsion Corporation to Hold Year-End 2018 Financial Results Conference Call on Friday, March 29, 2019
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the year ended December 31, 2018 and provide an update on its development programs for ThermoDox®, its proprietary...
Mar 04, 2019 08:30 am ET
Celsion Announces GEN-1 Data Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the oral presentation of data highlighting the safety, clinical response and translational data from its recently completed OVATION I Study. This Phase IB...
Feb 21, 2019 04:30 pm ET
Celsion Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that on February 19, 2019, the Compensation Committee of the Company's Board of Directors approved the grant of (i) inducement stock options (the “Inducement...
Feb 01, 2019 07:30 am ET
Consolidated Research: 2019 Summary Expectations for Southwest Airlines, Southern Copper, SEI Investments, Forward Air, Cincinnati Financial, and Celsion — Fundamental Analysis, Key Performance Indica
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Southwest Airlines Co. (NYSE:LUV), Southern Copper Corporation...
Jan 24, 2019 11:30 am ET
Celsion Corporation to Present at NobleConXV – Noble Capital Markets’ 15th Annual Investor Conference
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Jeffrey Church, Celsion’s Executive Vice President and Chief Financial Officer, will present at NobleConXV - Noble Capital Markets’ 15th Annual Investor...
Jan 17, 2019 08:30 am ET
Celsion Announces Publication of ThermoDox® Study Results in Radiology
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that results from the Phase I TARDOX trial of ThermoDox® conducted at the University of Oxford, United Kingdom, were published in the peer-reviewed journal,...
Jan 15, 2019 08:30 am ET
Celsion Announces Presentation of GEN-1 Data at Upcoming ASCO-SITC Clinical Immuno-Oncology Symposium
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that data from a Phase I study of GEN-1, its DNA-based immunotherapy for the localized treatment of ovarian cancer as an adjuvant to chemotherapy current...
Dec 18, 2018 08:00 am ET
Data Monitoring Committee (DMC) Completes Planned Safety and Data Review of Celsion’s Phase III OPTIMA Study of ThermoDox® for Treatment of Primary Liver Cancer
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the independent Data Monitoring Committee (DMC) for the Company's pivotal Phase III OPTIMA Study of ThermoDox® in combination with radiofrequency...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.